Research Analysts Offer Predictions for RAPT Therapeutics, Inc.’s Q1 2023 Earnings (NASDAQ:RAPT)

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2023 earnings estimates for shares of RAPT Therapeutics in a report issued on Tuesday, March 14th. SVB Leerink analyst T. Smith expects that the company will post earnings per share of ($0.62) for the quarter. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.86) per share. SVB Leerink also issued estimates for RAPT Therapeutics’ Q2 2023 earnings at ($0.67) EPS, Q3 2023 earnings at ($0.70) EPS, FY2023 earnings at ($2.74) EPS, FY2024 earnings at ($3.11) EPS, FY2025 earnings at ($3.51) EPS, FY2026 earnings at ($4.48) EPS and FY2027 earnings at ($0.59) EPS.

A number of other equities analysts also recently commented on RAPT. Piper Sandler reduced their price objective on shares of RAPT Therapeutics from $34.00 to $33.00 in a report on Thursday, December 8th. Wells Fargo & Company reduced their price objective on shares of RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, January 4th. Guggenheim reduced their price objective on shares of RAPT Therapeutics from $55.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday. Cantor Fitzgerald reduced their price objective on shares of RAPT Therapeutics from $44.00 to $40.00 in a report on Wednesday. Finally, HC Wainwright cut their price target on shares of RAPT Therapeutics from $50.00 to $43.00 and set a “buy” rating for the company in a report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $41.38.

RAPT Therapeutics Stock Performance

NASDAQ:RAPT opened at $18.94 on Friday. The company has a 50-day moving average of $27.10 and a 200-day moving average of $23.28. The company has a market capitalization of $649.45 million, a price-to-earnings ratio of -7.34 and a beta of 0.46. RAPT Therapeutics has a 52 week low of $9.85 and a 52 week high of $32.45.

Institutional Investors Weigh In On RAPT Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its position in RAPT Therapeutics by 0.3% in the 2nd quarter. Deutsche Bank AG now owns 289,114 shares of the company’s stock valued at $5,277,000 after acquiring an additional 778 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of RAPT Therapeutics by 6.9% during the 3rd quarter. MetLife Investment Management LLC now owns 13,805 shares of the company’s stock worth $332,000 after buying an additional 886 shares during the period. New England Capital Financial Advisors LLC acquired a new stake in shares of RAPT Therapeutics during the 4th quarter worth approximately $28,000. Great West Life Assurance Co. Can acquired a new stake in shares of RAPT Therapeutics during the 3rd quarter worth approximately $28,000. Finally, Legal & General Group Plc grew its position in shares of RAPT Therapeutics by 14.1% during the 4th quarter. Legal & General Group Plc now owns 10,278 shares of the company’s stock worth $204,000 after buying an additional 1,268 shares during the period.

Insider Activity at RAPT Therapeutics

In related news, insider William Ho sold 5,000 shares of RAPT Therapeutics stock in a transaction dated Thursday, December 29th. The shares were sold at an average price of $18.03, for a total transaction of $90,150.00. Following the completion of the transaction, the insider now directly owns 37,650 shares of the company’s stock, valued at approximately $678,829.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other RAPT Therapeutics news, insider William Ho sold 5,000 shares of the firm’s stock in a transaction dated Thursday, December 29th. The shares were sold at an average price of $18.03, for a total value of $90,150.00. Following the completion of the sale, the insider now owns 37,650 shares in the company, valued at approximately $678,829.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Wendye Robbins acquired 2,500 shares of the stock in a transaction on Tuesday, March 14th. The stock was bought at an average price of $18.99 per share, with a total value of $47,475.00. Following the transaction, the director now directly owns 14,900 shares in the company, valued at approximately $282,951. The disclosure for this purchase can be found here. Insiders sold 20,742 shares of company stock valued at $532,352 in the last ninety days. Insiders own 5.00% of the company’s stock.

RAPT Therapeutics Company Profile

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.